Polycystic ovary syndrome, better known as PCOS, has been one of the most recognised hormonal conditions affecting women for decades. But in 2026, something significant changed.

An international group of experts announced that PCOS would be renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS, reflecting growing understanding that the condition involves far more than the ovaries [1].

The name change is particularly relevant for women approaching perimenopause because PCOS does not simply disappear when periods become less regular or eventually stop. Hormonal symptoms may change, but metabolic concerns such as insulin resistance, cholesterol, weight management and cardiovascular risk may remain important.

NICE is also developing its first comprehensive UK guideline specifically for PMOS, with final publication expected in December 2026 [2].

So what does this change actually mean, and what should women with PCOS or PMOS know as they approach midlife?

Why Has PCOS Been Renamed PMOS?

The traditional name “polycystic ovary syndrome” has always been slightly misleading.

Despite the name, women do not need to have polycystic ovaries to have the condition.

PCOS can involve several interconnected systems, including:

• Reproductive hormones
• Androgen levels
• Insulin and glucose regulation
• Cholesterol and blood fats
• Weight regulation
• Fertility
• Skin and hair
• Psychological wellbeing

The newer term Polyendocrine Metabolic Ovarian Syndrome aims to reflect this wider picture.

“Polyendocrine” recognises that several hormonal systems can be involved.

“Metabolic” acknowledges the important relationship with insulin resistance, glucose regulation, weight and cardiovascular risk.

“Ovarian” recognises the reproductive and ovarian component without suggesting that visible ovarian cysts are essential for diagnosis.

The change therefore represents more than new terminology. It reflects a broader understanding of the condition as a lifelong hormonal and metabolic health issue.

Does PCOS Now Have a Completely Different Diagnosis?

No.

The name may be changing, but this does not suddenly invalidate previous PCOS diagnoses.

It also does not mean that a woman needs to be retested simply because the terminology has changed.

Diagnostic assessment still considers features such as:

• Irregular or absent ovulation
• Irregular menstrual cycles
• Signs of increased androgen activity
• Raised androgen levels on blood testing
• Ovarian appearance where imaging is appropriate
• Other conditions that could explain similar symptoms

Importantly, PCOS or PMOS cannot be diagnosed from a blood test alone.

Blood tests can support investigation and help assess hormonal and metabolic health, but the results need to be interpreted alongside symptoms, menstrual history, medical history and sometimes imaging.

What Happens to PCOS During Perimenopause?

This is where the picture becomes particularly interesting.

Perimenopause itself can cause irregular periods, hormonal fluctuations, changes in weight, acne, hair changes and metabolic disruption.

Many of these features overlap with PCOS.

Women who have spent years managing PCOS may therefore find it difficult to work out whether a new symptom comes from their existing condition, perimenopause or both.

Research published in 2026 also suggests that women with PCOS may experience the menopause transition differently.

A population study published in the Acta Obstetricia et Gynecologica Scandinavica found that women with PCOS showed signs of a later menopause transition and, at age 46, reported fewer menopause symptoms than women without PCOS [3].

This does not mean women with PCOS are protected from menopause symptoms. Individual experiences vary considerably.

It does reinforce the fact that PCOS and menopause interact in ways we are still learning about.

Do PCOS Symptoms Disappear After Menopause?

Some reproductive symptoms may become less relevant after menstruation stops, but the underlying hormonal and metabolic characteristics do not necessarily disappear.

Research suggests that higher androgen levels can persist after menopause in some women with a history of PCOS [4].

Metabolic factors may also remain relevant, including:

• Insulin resistance
• Central abdominal weight
• High blood pressure
• Abnormal cholesterol and triglycerides
• Increased type 2 diabetes risk

This is one reason the new PMOS terminology places greater emphasis on metabolic health rather than focusing solely on periods and fertility.

Why Metabolic Health Matters

PCOS has long been associated with insulin resistance.

Insulin is the hormone responsible for moving glucose from the bloodstream into cells where it can be used for energy.

When cells become less responsive to insulin, the body may compensate by producing more of it.

Over time this can contribute to:

• Weight gain
• Difficulty losing weight
• Increased abdominal fat
• Prediabetes
• Type 2 diabetes
• Changes in cholesterol and triglycerides

These issues can become particularly relevant in perimenopause because declining oestrogen, ageing, changing body composition and loss of muscle mass may also influence metabolic health.

What Does the New NICE Guidance Say?

NICE is currently developing dedicated guidance for PMOS.

The final guideline is expected in December 2026, so recommendations may still change.

However, the draft guidance has already highlighted an important shift towards long-term health monitoring [2].

NICE has proposed that people aged 10 and over with PMOS should receive regular review to consider:

• Current symptoms
• Medication
• Cardiovascular health
• Diabetes risk
• Psychological wellbeing
• Long-term complications

This reinforces the idea that PMOS should not be viewed simply as a reproductive problem that becomes irrelevant once fertility is no longer a priority.

PCOS, PMOS and Heart Health

Research continues to examine the relationship between PCOS and cardiovascular disease.

A large 2026 study found an association between PCOS and increased long-term risk of certain cardiac rhythm problems [5].

Other research has shown relationships between PCOS and cardiovascular risk factors including:

• High blood pressure
• Insulin resistance
• Diabetes
• High triglycerides
• Lower HDL cholesterol

Weight and metabolic health appear to explain part of this increased risk, highlighting the value of addressing these factors before and during menopause.

This does not mean every woman with PCOS will develop cardiovascular disease.

It means that cardiovascular and metabolic health deserve appropriate attention as part of long-term care.

What Blood Tests Can Be Useful?

Blood testing may help provide a broader picture when investigating symptoms or monitoring established PCOS or PMOS.

Depending on the individual, useful markers might include:

Female reproductive hormones

FSH, LH and oestradiol can add clinical context, although hormone levels vary significantly throughout the menstrual cycle.

Testosterone and SHBG

Testosterone and sex hormone binding globulin can help assess androgen status.

A Free Androgen Index can also be calculated from these measurements.

Prolactin

Raised prolactin can cause irregular periods and other symptoms that may overlap with PCOS.

Thyroid function

Thyroid disorders can also cause irregular periods, weight changes, fatigue and hair symptoms.

HbA1c and glucose

These help assess blood sugar regulation and diabetes risk.

Cholesterol and triglycerides

A lipid profile helps assess cardiovascular and metabolic health.

AMH

Anti-Müllerian Hormone can provide information about ovarian activity, but should not be viewed as a standalone diagnostic test for PMOS.

The Menopause Medic PCOS Panel

The Menopause Medic offers a dedicated PCOS Panel designed to look at both sides of the condition, hormonal and metabolic.

The panel includes:

• Follicle Stimulating Hormone
• Luteinising Hormone
• Oestradiol
• Progesterone
• Prolactin
• Testosterone
• Sex Hormone Binding Globulin
• Free Androgen Index
• AMH
• Advanced thyroid testing
• HbA1c
• Glucose
• Lipid profile

The test can support investigation or monitoring, but results should always be interpreted within the wider clinical picture.

A blood panel cannot diagnose PCOS or PMOS by itself.

PCOS, Weight and Perimenopause

Weight management can become particularly challenging when PCOS and perimenopause overlap.

Insulin resistance, sleep disturbance, loss of muscle mass and hormonal fluctuations can all influence appetite, fat distribution and energy use.

Management may involve:

• Nutrition
• Resistance training
• Improved sleep
• Stress management
• Treatment of insulin resistance where appropriate
• Menopause treatment
• Medical weight management in suitable patients

For some women, GLP-1 based medications may be considered as part of a medically supervised weight management programme.

Treatment should focus on overall metabolic health rather than simply reaching a number on the scales.

Can Women With PCOS Use HRT?

Having PCOS does not automatically prevent a woman from using HRT.

When menopause symptoms occur, HRT suitability should be considered according to the same individual principles used for other women.

Assessment may include:

• Personal medical history
• Blood pressure
• Weight and metabolic health
• Cardiovascular risk
• Menstrual and bleeding history
• Individual symptoms
• Personal treatment preferences

A personalised menopause consultation can help determine whether HRT or another treatment approach is appropriate.

PCOS Is Not Only About Fertility

One of the most useful aspects of the shift from PCOS to PMOS is the recognition that the condition does not stop mattering once pregnancy is no longer a priority.

Midlife care should consider:

• Blood sugar
• Cholesterol
• Cardiovascular risk
• Weight and muscle health
• Hormone symptoms
• Psychological wellbeing
• Menopause transition

For women previously diagnosed with PCOS, perimenopause offers a useful opportunity to reassess the bigger health picture.

Support at The Menopause Medic

The Menopause Medic offers specialist hormonal and metabolic healthcare for women through perimenopause, menopause and beyond.

Alongside personalised menopause consultations, the clinic provides PCOS and hormone blood testing, comprehensive metabolic panels and medical weight management where clinically appropriate.

Face-to-face consultations are available in Berkhamsted and St Albans, with virtual appointments available across the UK.

References

[1] Monash University. International evidence-based guideline for Polyendocrine Metabolic Ovarian Syndrome, formerly PCOS. 2026.

[2] NICE. Polyendocrine Metabolic Ovarian Syndrome guideline. Draft guidance 2026, final publication expected December 2026.

[3] Lavi J et al. Women with PCOS have a later menopausal transition and a lower prevalence of menopausal symptoms at age 46. Acta Obstetricia et Gynecologica Scandinavica. 2026.

[4] Human Reproduction Update. PCOS during the menopausal transition and after menopause: systematic review and meta-analysis.

[5] Reinert MS et al. Polycystic Ovarian Syndrome and the Long-Term Risk of Arrhythmias. Circulation. 2026.

[6] The Menopause Medic. PCOS blood testing and diagnostic services.

Medical Disclaimer

This article is intended for general information and education only and does not constitute medical advice, diagnosis or treatment. PCOS or PMOS cannot be diagnosed using blood results alone. Speak to an appropriately qualified healthcare professional for individual assessment.